Abstract:The ALPINE trial was a randomized, open-label study comparing the efficacy and safety of zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Using patient-reported outcome (PRO) data from the ALPINE trial, this study aimed to investigate the associations between disease-specific patient-reported symptoms and the clinical outcomes of progression-free survival (PFS) and duration of response (DoR). After adjusting for baseline stratification factors, zanubrutinib was associated with lower PRO-based recurrent symptomatic deterioration than ibrutinib. Zanubrutinib also demonstrated significantly lower risk of disease progression and better DoR across all disease-specific patient-reported symptoms. Compared with ibrutinib, zanubrutinib demonstrated a 28% to 33% reduction in the risk of a PFS event after adjusting for global health status, physical functioning, role functioning, fatigue, pain, nausea and vomiting, diarrhea, and constipation (all P< .02). Similarly, zanubrutinib demonstrated a 31% to 51% reduced risk of shortened DoR after adjusting for the patient-reported scores (all P< .02). These are crucial aspects in clinical decision-making because they highlight zanubrutinib’s association with improved clinical outcomes and patient-reported symptomatology. These findings reinforce the enhanced efficacy profile of zanubrutinib in patients with R/R CLL/SLL by demonstrating its lower patient-reported symptom deterioration in addition to increased PFS and better DoR. This trial was registered at www.clinicaltrials.gov as NCT03734016.